The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase

Blood

Volumn 98, Issue 12, 2001, Pages 3205-3211

  Lee, Stephanie J ^{a,b,c,d,e,f,g,h,i}   Klein, John P ^{a,b,c,d,e,f,g,h,i}   Anasetti, Claudio ^{a,b,c,d,e,f,g,h,i}   Antin, Joseph H ^{a,b,c,d,e,f,g,h,i}   Loberiza, Fausto R ^{a,b,c,d,e,f,g,h,i}   Bolwell, Brian J ^{a,b,c,d,e,f,g,h,i}   Lemaistre, Charles F ^{a,b,c,d,e,f,g,h,i}   Litzow, Mark R ^{a,b,c,d,e,f,g,h,i}   Marks, David ^{a,b,c,d,e,f,g,h,i}   Waller, Edmund K ^{a,b,c,d,e,f,g,h,i}   Matlack, Marie ^{a,b,c,d,e,f,g,h,i}   Giralt, Sergio ^{a,b,c,d,e,f,g,h,i}   Horowitz, Mary M ^{a,b,c,d,e,f,g,h,i}  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NATIONAL MARROW DONOR PROGRAM   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f South Texas Cancer Institute   (United States)

^g MAYO CLINIC   (United States)

^h BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; HYDROXYUREA; METHOTREXATE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DONOR; DRUG EFFECT; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035760886     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.12.3205     Document Type: Article

References (32)

1. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia [see comments]. N Engl J Med. 1998;338:962-968.
2. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood. 2000;95:2219-2225.
3. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia [see comments]. N Engl J Med. 1994;330:820-825.
4. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114:532-538.
5. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. The Leukemia Service. Ann Intern Med. 1995;122:254-261.
6. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906-916.
7. Ohnishi K, Tomonaga M, Kamada N, et al. A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. Leuk Res. 1998;22:779-786.
8. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345:1392-1397.
9. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]. Blood. 1994;84:4064-4077.
10. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997;89:1616-1620.
11. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group [see comments]. N Engl J Med. 1997;337:223-229.
12. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-a2b for chronic myeloid leukemia. Blood. 1998;91:2713-2721.
13. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541-1548.
14. Baron S, Tyring SK, Fleischmann WR Jr, et al. The interferons: mechanisms of action and clinical applications [see comments]. JAMA. 1991;266:1375-1383.
15. Giralt SA, Kantarjian HM, Talpaz M, et al. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993;11:1055-1061.
16. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981-2990.
17. Shepherd P, Richards S, Allan N. Survival after allogeneic bone marrow transplantation (BMT) in patients randomised into a trial of IFN-α versus chemotherapy: no significant adverse effect of prolonged IFN-α administration. Blood. 1995;86:94a.
18. Holler E, Schleuning M, Ledderose G, Mittermuller H, Wimanns W, Kolb HJ. IFN alpha prior to allogeneic BMT in patients with chronic myelogenous leukemia [abstract 383]. Ann Hematol. 1995;1996:A96.
19. Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394-401.
20. Zuffa E, Bandini G, Bonini A, et al. Prior treatment with α-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica. 1998;83:231-236.
21. Tomas JF, Lopez-Lorenzo JL, Requena MJ, et al. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 1998;22:47-51.
22. Pigneux A, Tanguy ML, Michallet M, et al. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for CML. Blood. 1998;92:495a.
23. Hehlmann R, Hochhaus A, Kolb HJ, et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood. 1999;94:3668-3677.
24. Beelen DW, Elmaagacli AH, Schaefer UW. The adverse influence of pretransplant interferon-α (IFN-α) on transplant outcome after marrow transplantation for chronic phase chronic myelogenous leukemia increases with the duration of IFN-α exposure [letter]. Blood. 1999;93:1779-1780.
25. Giralt S, Szydlo R, Goldman JM, et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry [in process citation]. Blood. 2000;95:410-415.
26. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. The Italian Cooperative CML Study Group. Blood. 1984;63:789-799.
27. Sokal JE, Baccarani M, Tura S, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985;66:1352-1357.
28. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-858.
29. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
30. Tura S. Cytarabine increases karyotypic response in alpha-IFN treated chronic myeloid leukemia patients: results of a national prospective randomized trial. Blood. 1998;92:317a.
31. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
32. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.